Our Science

Our
foundational
work
in
healthy
aging
harnesses
the
microbiota
of
fruits
and
vegetables
to
address
the
most
common
age-related
inflammatory
disorders.

Bone Health

Bone density loss is a natural result of the aging process. Our discoveries in bone health have yielded a safe, clinically validated way to slow bone loss and, as a result, improve bone density.

Bone Health

Rheumatoid Arthritis

Psoriatic Arthritis

Cellular health

Menopause

Our Scientific
Process

Microbe Isolation

Using our novel approach, our premier team of scientists isolates the microbes naturally found in fruits, vegetables, and fermented foods and sequences each isolate’s full genome for our microbial library.

  • Over 5000 microbial isolates
  • Over 16M genes
  • Over 7M biosynthetic clusters
Microbe Isolation

Days

Genomic Sequencing

With deep sequencing technology, we sequence the full genome of the isolates in our microbial library.

  • Over 1,400 high-quality microbial genomes
Genomic Sequencing

Days

In silico Predictions

We leverage AI to mine our proprietary genomic databases to accurately and precisely identify the most promising immunomodulatory candidates to advance to in vitro validation.

  • Thousands of strains identified
In silico Predictions

Days

DMA™ Product Formulation

Selected strains are developed into Defined Microbial Assemblages (DMA™), combinations of bacteria, fungi, and prebiotic plant fibers that synergize to produce stronger anti-inflammatory responses than the sum of their parts.

  • Dozens of strains selected
DMA™ Product Formulation

1-2 months

Preclinical testing

Lead candidate DMA™ medical food products are rigorously evaluated using gold-standard preclinical disease models for safety and efficacy.

  • 1-5 DMA™ candidates
Preclinical testing

3-6 months

Clinical validation

We employ randomized, double-blind, placebo-controlled human clinical food trials to validate our DMA™ medical foods. These trials are designed by renowned physicians, using clinical testing with the same rigor as pharmaceutical products.

  • 1 DMA™
Clinical validation

6-24 months

Advisors

We
continue
to
explore
novel
applications
of
Microscope
Technology™

Pipeline
Launched
SBD111

SBD111

Clinically validated to slow bone loss (clinical study pending peer review & publication)

Toggle for Pipeline
July 2025

SBD121

Being developed to address the dietary needs of rheumatoid arthritis

Toggle for Pipeline
TBD

SBDXXX

Being developed to address the dietary needs of psoriatic arthritis

Toggle for Pipeline
TBD

SBDXXX

Being developed to address the dietary needs of cellular aging

Toggle for Pipeline

Scientific
Publications

Food and Chemical Toxicology – 2024

September 1, 2024

Food safety assessment and 28-day toxicity study of the synbiotic Medical Food consortium SBD121.

Easson DD, Murphy VA, Ballok AE, Soto-Giron MJ, Miller KJ, Charbonneau MR, Schott EM, Greene T, Rodricks J, Toledo GV

Gut Microbes – 2023

September 10, 2023

The edible plant microbiome: evidence for the occurrence of fruit and vegetable bacteria in the human gut

Wicaksono W, Cernava T, Wassermann B, Abdelfattah A, Soto-Giron M, Toledo G, Virtanen S, Knip M, Hyöty H, Berg G

Clinical trial: SBD121, a Synbiotic Medical Food for RA Management – 2023

January 1, 2023

The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the dietary management of symptoms of early rheumatoid arthritis (RA).

Journal of Microbiology & Experimentation – 2023

January 1, 2023

Randomized clinical trial to test the safety and tolerability of SBD111, an optimized synbiotic medical food combination designed for the dietary management of the metabolic processes underlying osteopenia and osteoporosis.

Sahni S, Schott E, Caroll D, Soto-Giron M, Corbett S, Toledo G, Kiel D.

Nature Biopharma Dealmakers – 2022

January 1, 2022

Managing inflammatory diseases and aging with edible plant microbes

Clinical trial: Food Trial Evaluating the Efficacy of SBD111 Versus Placebo for the Clinical Dietary Management of the Metabolic Processes of Osteopenia – 2022

January 1, 2022

The aim of the trial is to determine if the SYNBIOTIC (prebiotic and probiotic), provided twice daily (capsule) will help support skeletal health in otherwise healthy postmenopausal women in the early years postmenopause (1-6 years post last menstruation) over a 12-month period.

Am Journal Physiol Endocrinol Metab – 2022

April 1, 2022

Development of a synbiotic that protects against ovariectomy induced trabecular bone loss.

Lawenius L, Gustafsson KL, Wu J, Nilsson KH, Movérare-Skrtic S, Schott EM, Soto-Girón MJ, Toledo GV, Sjögren K, Ohlsson C.

Food and Chemical Toxicology – 2022

October 1, 2022

Food safety assessment and toxicity study of the synbiotic consortium SBD111.

Easson DD, Murphy VA, Ballok AE, Soto-Giron MJ, Schott EM, Rodricks J, Toledo GV

Scientific Reports – 2021

December 15, 2021

The Edible Plant Microbiome represents a diverse genetic reservoir with functional potential in the human host

Soto-Giron MJ, Kim JN, Schott E, Tahmin C, Ishoey T, Mincer TJ, DeWalt J, Toledo G

Nutrients – 2020

July 9, 2020

Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study.

Palacios T, Vitetta L, Coulson S, Madigan CD, Lam YY, Manuel R, Briskey D, Hendy C, Kim JN, Ishoey T, Soto-Giron MJ, Schott EM, Toledo G, Caterson ID